We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+96.42%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$432M
AUM Growth
+$81M
Cap. Flow
-$48.6M
Cap. Flow %
-11.24%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
4
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$24.1M
2
HRMY icon
Harmony Biosciences
HRMY
+$15.8M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$7.99M
4
VRNA
Verona Pharma
VRNA
+$678K
5
PHVS icon
Pharvaris
PHVS
+$74.1K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
1
DELISTED
Ventyx Biosciences
VTYX
$175M 40.48%
5,011,536
– –
ALXO icon
2
ALX Oncology
ALXO
$273M
$92.8M 21.48%
9,699,925
– –
CINC
3
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$61.1M 14.14%
1,862,256
-282,779
-13% -$7.99M
HRMY icon
4
Harmony Biosciences
HRMY
$2.05B
$49.9M 11.53%
1,125,673
-323,047
-22% -$15.8M
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$20.3M 4.7%
596,483
-1,575,181
-73% -$24.1M
PHVS icon
6
Pharvaris
PHVS
$2.39B
$17.6M 4.08%
2,296,710
-4,741
-0.2% -$74.1K
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$13.4M 3.11%
2,759,791
– –
ELEV
8
DELISTED
Elevation Oncology
ELEV
$2.11M 0.49%
1,866,339
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
– –
-161,897
Closed -$678K

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q3 2022 Portfolio in Review

As of Q3 2022, venBio Partners held 9 positions worth $432M, up 23% from $351M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $48.6M in Q3 2022, closing 1 position and reducing 4 holdings. Its most notable exit was Verona Pharma, an estimated $678K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q3 2022 reduction was Akero Therapeutics, cutting an estimated $24.1M.
  • venBio Partners fully exited Verona Pharma in Q3 2022, selling an estimated $678K.
  • venBio Partners's ten largest holdings make up 100% of its $432M portfolio in Q3 2022.
  • venBio Partners opened 0 new positions and closed 1 in Q3 2022.
  • venBio Partners's portfolio value rose 23% quarter-over-quarter to $432M.

Based on venBio Partners's 13F filing for Q3 2022, filed 14 Nov 2022.